GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ondine Biomedical Inc (FRA:VF5) » Definitions » Capex-to-Operating-Income

Ondine Biomedical (FRA:VF5) Capex-to-Operating-Income : 0.00 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Ondine Biomedical Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Ondine Biomedical's Capital Expenditure for the six months ended in Dec. 2024 was €0.00 Mil. Its Operating Income for the six months ended in Dec. 2024 was €-7.79 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Ondine Biomedical Capex-to-Operating-Income Historical Data

The historical data trend for Ondine Biomedical's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ondine Biomedical Capex-to-Operating-Income Chart

Ondine Biomedical Annual Data
Trend Dec09 Dec10 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ondine Biomedical Semi-Annual Data
Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ondine Biomedical's Capex-to-Operating-Income

For the Biotechnology subindustry, Ondine Biomedical's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ondine Biomedical's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ondine Biomedical's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Ondine Biomedical's Capex-to-Operating-Income falls into.


;
;

Ondine Biomedical Capex-to-Operating-Income Calculation

Ondine Biomedical's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.007) / -13.034
=N/A

Ondine Biomedical's Capex-to-Operating-Income for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -7.785
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ondine Biomedical  (FRA:VF5) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Ondine Biomedical Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Ondine Biomedical's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Ondine Biomedical Business Description

Traded in Other Exchanges
Address
1100 Melville Street, Suite 888, Vancouver, BC, CAN, V6E4A6
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.

Ondine Biomedical Headlines

No Headlines